FHTX
Price:
$6.63
Market Cap:
$368.58M
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor...[Read more]
Industry
Biotechnology
IPO Date
2020-10-23
Stock Exchange
NASDAQ
Ticker
FHTX
According to Foghorn Therapeutics Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -3.70. This represents a change of -11.64% compared to the average of -4.19 of the last 4 quarters.
The mean historical PE Ratio of Foghorn Therapeutics Inc. over the last ten years is -8.42. The current -3.70 PE Ratio has changed 4.29% with respect to the historical average. Over the past ten years (40 quarters), FHTX's PE Ratio was at its highest in in the December 2021 quarter at 1.24. The PE Ratio was at its lowest in in the December 2020 quarter at -1445.82.
Average
-8.42
Median
-9.46
Minimum
-13.51
Maximum
-2.44
Discovering the peaks and valleys of Foghorn Therapeutics Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 12.86%
Maximum Annual PE Ratio = -2.44
Minimum Annual Increase = -70.40%
Minimum Annual PE Ratio = -13.51
Year | PE Ratio | Change |
---|---|---|
2023 | -2.75 | 12.86% |
2022 | -2.44 | -70.40% |
2021 | -8.24 | -22.94% |
2020 | -10.69 | -17.23% |
2019 | -12.91 | -4.39% |
The current PE Ratio of Foghorn Therapeutics Inc. (FHTX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-4.47
5-year avg
-7.40
10-year avg
-8.42
Foghorn Therapeutics Inc.’s PE Ratio is less than C4 Therapeutics, Inc. (-2.58), greater than Cyteir Therapeutics, Inc. (-9.12), less than Prelude Therapeutics Incorporated (-0.55), greater than Rezolute, Inc. (-5.29), less than Shattuck Labs, Inc. (-0.87), greater than Monte Rosa Therapeutics, Inc. (-6.19), greater than Kymera Therapeutics, Inc. (-20.25), greater than Nurix Therapeutics, Inc. (-8.46), less than Molecular Partners AG (-2.64), less than MediciNova, Inc. (-0.04), greater than Anebulo Pharmaceuticals, Inc. (-4.81), greater than Champions Oncology, Inc. (-17.25), less than PMV Pharmaceuticals, Inc. (-1.59), greater than Stoke Therapeutics, Inc. (-6.71), less than Century Therapeutics, Inc. (-0.96), greater than Edgewise Therapeutics, Inc. (-23.72), greater than Mineralys Therapeutics, Inc. (-4.02), greater than Cullinan Oncology, Inc. (-5.12),
Company | PE Ratio | Market cap |
---|---|---|
-2.58 | $276.00M | |
-9.12 | $108.71M | |
-0.55 | $52.28M | |
-5.29 | $304.78M | |
-0.87 | $61.11M | |
-6.19 | $554.02M | |
-20.25 | $2.88B | |
-8.46 | $1.46B | |
-2.64 | $211.78M | |
-0.04 | $110.35M | |
-4.81 | $38.12M | |
-17.25 | $58.59M | |
-1.59 | $82.28M | |
-6.71 | $665.27M | |
-0.96 | $125.42M | |
-23.72 | $2.98B | |
-4.02 | $615.14M | |
-5.12 | $733.67M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Foghorn Therapeutics Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Foghorn Therapeutics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Foghorn Therapeutics Inc.'s PE Ratio?
How is the PE Ratio calculated for Foghorn Therapeutics Inc. (FHTX)?
What is the highest PE Ratio for Foghorn Therapeutics Inc. (FHTX)?
What is the 3-year average PE Ratio for Foghorn Therapeutics Inc. (FHTX)?
What is the 5-year average PE Ratio for Foghorn Therapeutics Inc. (FHTX)?
How does the current PE Ratio for Foghorn Therapeutics Inc. (FHTX) compare to its historical average?